原发性血小板增多症

Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.

• 摘要

Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. Haematologica. 2004;89:215-232.

• 全文
• 摘要

1.  Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4:33-40.

• 全文
• 摘要

2.  Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231-239.

• 全文
• 摘要

3.  Michiels JJ, de Raeve H, Hebeda K, et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res. 2007;31:1031-1038.

• 摘要

4.  Harrison CN, Bareford D, Butt N, et al; British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352-375.

• 全文
• 摘要

5.  Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.

• 摘要

6.  Michiels JJ, van Genderen PJ, Jansen PH, et al. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma. 1996;1:65-70.

• 摘要

7.  Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001;66:152-159.

• 摘要

8.  Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10-15.

• 摘要

9.  Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias: clinical evolutionary and biological data. Cancer. 1986;58:2440-2447.

• 摘要

10.  Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.

• 全文
• 摘要

11.  Forehand CC, Cribb J, May JR. Examination of the relationship between antimicrobials and thrombocytosis. Ann Pharmacother. 2012;46:1425-1429.

• 摘要

12.  Wiestner A, Schlemper RJ, van der Maas AP, et al. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18:49-52.

• 摘要

13.  Picardi M, Martinelli V, Ciancia R, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood. 2002;99:4228-4230.

• 摘要

14.  Spanoudakis E, Margaritis D, Kotsianidis I, et al. Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation. Leuk Res. 2008;32:1593-1596.

• 摘要

15.  Tefferi A, Barbui T. Personalized management of essential thrombocythemia - application of recent evidence to clinical practice. Leukemia. 2013;27:1617-1620.

• 全文
• 摘要

16.  Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia. Blood. 2011;117:1472-1482.

• 全文
• 摘要

17.  Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.

• 摘要

18.  Ruggeri M, Tosetto A, Frezzato M, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470-475.

• 摘要

19.  Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994;97:374-378.

• 摘要

20.  Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67-73.

• 摘要

21.  Squizzato A, Romualdi E, Passamonti F, et al. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2013;(4):CD006503.

• 全文
• 摘要

22.  Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.

• 全文
• 摘要

23.  Elliott MA, Tefferi A. Interferon-alfa therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997;23:463-472.

• 摘要

24.  Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:285-293.

• 摘要

25.  Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood. 2002;99:1602-1609.

• 摘要

26.  Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica. 2004;89:1394-1395.

• 摘要

27.  Taft EG, Babcock RB, Scharfman WB, et al. Plateletpheresis in the management of thrombocytosis. Blood. 1977;50:927-933.

• 全文
• 摘要

28.  Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. Haematologica. 2004;89:215-232.

• 全文
• 摘要

29.  De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372-380.

• 全文
• 摘要

30.  Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720-1728.

• 全文
• 摘要

31.  Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920-928.

• 全文
• 摘要

32.  Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275-290.

• 摘要

33.  Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.

• 摘要